Close Follow-Up of Patients with Neurofibromatosis Type 1 Reduces the Incidence of Malignant Peripheral Nerve Sheath Tumour

Affiliations

¹ Centre for Human Genetics, University Hospitals Leuven, KU Leuven, 3000 Leuven, Belgium.
² Department of Paediatric Oncology, University Hospitals Leuven, 3000 Leuven, Belgium.
³ Department of Paediatric Oncology, Princess Máxima Centre for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
⁴ Department of Surgical Oncology, University Hospitals Leuven, 3000 Leuven, Belgium.
⁵ Radiology Department, University Hospitals Leuven, 3000 Leuven, Belgium.
⁶ Department of Pathology, University Hospitals Leuven, KU Leuven, 3000 Leuven, Belgium.
⁷ Nuclear Medicine, University Hospitals Leuven, and Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, 3000 Leuven, Belgium.
⁸ Department of Neurosurgery, University Hospitals Leuven, 3000 Leuven, Belgium.

Maria Pia Iasella et al. Cancers (Basel). 2025.

. 2025 Apr 12;17(8):1306.

doi: 10.3390/cancers17081306.

¹ Centre for Human Genetics, University Hospitals Leuven, KU Leuven, 3000 Leuven, Belgium.
² Department of Paediatric Oncology, University Hospitals Leuven, 3000 Leuven, Belgium.
³ Department of Paediatric Oncology, Princess Máxima Centre for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
⁴ Department of Surgical Oncology, University Hospitals Leuven, 3000 Leuven, Belgium.
⁵ Radiology Department, University Hospitals Leuven, 3000 Leuven, Belgium.
⁶ Department of Pathology, University Hospitals Leuven, KU Leuven, 3000 Leuven, Belgium.
⁷ Nuclear Medicine, University Hospitals Leuven, and Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, 3000 Leuven, Belgium.
⁸ Department of Neurosurgery, University Hospitals Leuven, 3000 Leuven, Belgium.

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic condition with a birth incidence of one in 2000 to one in 3000 [...].

Keywords: ANNUBP; MPNST; WB-DW/MRI; neurofibromatosis type 1.

E.L. receives occasional consultancy fees from Alexion and Springworks Therapeutics. The other authors declare no conflicts of interest.

1. Huson S.M., Harper P.S., Compston D.A. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Pt 6Brain A J. Neurol. 1988;111:1355–1381. doi: 10.1093/brain/111.6.1355. - DOI - PubMed
1. Lammert M., Friedman J.M., Kluwe L., Mautner V.F. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch. Dermatol. 2005;141:71–74. doi: 10.1001/archderm.141.1.71. - DOI - PubMed
1. Kallionpää R.A., Uusitalo E., Leppävirta J., Pöyhönen M., Peltonen S., Peltonen J. Prevalence of neurofibromatosis type 1 in the Finnish population. Genet. Med. Off. J. Am. Coll. Med. Genet. 2018;20:1082–1086. doi: 10.1038/gim.2017.215. - DOI - PubMed
1. Gutmann D.H., Wood D.L., Collins F.S. Identification of the neurofibromatosis type 1 gene product. Proc. Natl. Acad. Sci. USA. 1991;88:9658–9662. doi: 10.1073/pnas.88.21.9658. - DOI - PMC - PubMed
1. Cichowski K., Jacks T. NF1 Tumor Suppressor Gene Function: Narrowing the GAP. Cell. 2001;104:593–604. doi: 10.1016/S0092-8674(01)00245-8. - DOI - PubMed